Jorge A. Gallardo-Cartagena

Identifying Implementation Gaps in the HIV Prevention Cascade among Peruvian Men Who Have Sex with Men

Jorge A. Gallardo-Cartagena, David Oliveros, Robinson Cabello, Carlos Benites et autres

pe, us, bo (code pays fourni par la source)

Preferences for mHealth Features to Support Engagement in the HIV Preexposure Prophylaxis Cascade Among Men Who Have Sex With Men in Peru: Cross-Sectional Online Survey

Jorge A. Gallardo-Cartagena, Dora Leidy Geraldine German-Quiñones, Kelika A. Konda, Susan Buchbinder et autres

Background: Despite policy-level progress, implementation of oral HIV preexposure prophylaxis (PrEP) remains limited in Latin America. In Peru, men who have sex with men (MSM) account for most new HIV diagnoses, yet uptake remains low. Widespread smartphone ownership and the use of …

pe, us (code pays fourni par la source)

Coordinated Immune Response Distinguishes Duration of SARS-CoV-2 Viral Particle Shedding in Humans

M. Juliana McElrath, April K. Randhawa, Sherry Stanfield-Oakley, Nicole L. Yates et autres

us (code pays fourni par la source)

Challenges and Opportunities for Improved Tuberculosis and HIV Prevention in South America

Cender Udai Quispe-Juli, Jorge A. Gallardo-Cartagena, Larissa Otero, B. C. O. P. Andrade et autres

Tuberculosis (TB) and human immunodeficiency virus (HIV) cause significant morbidity and mortality in South America. Despite the advances in active case finding and early treatment initiation as core strategies to decrease TB and HIV transmissions, additional efforts are needed to achieve control …

pe, py, us, br, co (code pays fourni par la source)

Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humans

Daniel J. Schuster, Shuying S. Li, Dieter Mielke, Kelly E. Seaton et autres

= 223). While PVS participants demonstrated lower overall SARS-CoV-2-specific antibody magnitudes, over-representation analysis revealed that immune feature magnitude alone could not fully explain cohort differences. Hierarchical clustering and network analyses identified more highly coordinated antibody responses, T cell activation, and Fc-mediated function …

us, pe (code pays fourni par la source)

Implementation of Daily Oral PrEP at HIV/AIDS Service Organizations in Lima, Peru: Early Findings From the PrEP PERU Demonstration Study

Pamela Ramírez, Alexander Lankowski, Jorge A. Gallardo-Cartagena, Pedro Gonzáles et autres

BackgroundDespite global declines in HIV incidence, new infections continue to rise in Latin America. Oral tenofovir-based HIV pre-exposure prophylaxis (PrEP) is effective and can reduce incidence where implemented. PrEP PERU is a prospective cohort study evaluating daily oral PrEP delivery at HIV/AIDS …

pe, Afrique du Sud, us (code pays fourni par la source)

High Willingness to Use and Recommend Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention in Peru

Jorge A. Gallardo-Cartagena, Dora Leidy Geraldine German-Quiñones, Fanny G. Rosas-Benancio, Karla T. Tafur et autres

BACKGROUND: Bacterial sexually transmitted infections (STIs) remain prevalent among men who have sex with men (MSM) and transgender women (TGW) in Peru. Doxycycline postexposure prophylaxis (doxy-PEP) is a promising prevention strategy, but data from Latin America remain limited. METHODS: We conducted 2 …

pe, us, es (code pays fourni par la source)

Preferences for Mobile Health Tools to Support PrEP Use Among Men Who Have Sex with Men in Peru: A Cross-Sectional Survey (Preprint)

Jorge A. Gallardo-Cartagena, Dora Leidy Geraldine German-Quiñones, Kelika A. Konda, Susan Buchbinder et autres

BACKGROUND Despite policy-level progress, the implementation of oral pre-exposure prophylaxis (PrEP) for HIV prevention remains limited in Latin America. In Peru, men who have sex with men (MSM) represent the majority of new HIV diagnoses, yet PrEP uptake remains low. The widespread …

Oral Preexposure Prophylaxis Uptake and Discontinuation in the HIV Vaccine Trials Network 704/HIV Prevention Trials Network 085 Study: Implications for Biomedical Human Immunodeficiency Virus Prevention Trials

Kevin Gillespie, Jorge A. Gallardo-Cartagena, Moni B. Neradilek, Deborah Donnell et autres

Background: HIV Vaccine Trials Network (HVTN) 704/085, a placebo-controlled clinical trial assessing the efficacy of VRC01 broadly neutralizing antibody infusion for HIV prevention, offered oral preexposure prophylaxis (PrEP) as the standard of prevention at no cost to participants. Methods: We characterized features …

us (code pays fourni par la source)

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

Colleen F. Kelley, Maribel Acevedo-Quiñones, Allison L. Agwu, Anchalee Avihingsanon et autres

BACKGROUND: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of human immunodeficiency virus (HIV) infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men, and gender-nonbinary persons is unclear. METHODS: …

us, pr, th, br, ar, bd, pe, Afrique du Sud, mx, gb (code pays fourni par la source)

Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083

Meredith E. Clement, Brett Hanscom, Daniel Haines, José A. Bazan et autres

BACKGROUND: Sexually transmitted infections (STIs) have been shown to facilitate human immunodeficiency virus (HIV) transmission and acquisition. HPTN 083, a global clinical trial, demonstrated superiority of long-acting cabotegravir (CAB-LA) versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV prevention among transgender women …

us, th, jp, br, gb, au (code pays fourni par la source)

Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxis

Jessica M. Fogel, Estelle Piwowar-Manning, Amber Moser, Tinia Hill et autres

Detection of HIV infection may be challenging in persons using long-acting cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) due to viral suppression and reduced/delayed antibody production. We evaluated two point-of-care tests for detecting HIV infection in persons who received CAB-LA in the HPTN 083 …

us, pe, ar, br (code pays fourni par la source)